Home » SERENEX RAISES $30 MILLION IN SERIES C FINANCING
SERENEX RAISES $30 MILLION IN SERIES C FINANCING
Serenex, Inc., an integrated oncology-focused drug discovery and development company, announced today that it has raised $30 million in a Series C private placement of preferred stock. Ritchie Capital led the round which included existing investors Intersouth Partners, Lilly Ventures, Mediphase Venture Partners, Takeda Research Investment and Seaflower Ventures. Serenex also announced that it has in-licensed worldwide rights to develop and commercialize SNX-1012 for chemotherapy and radiation-induced oral mucositis from Mucosal Therapeutics, LLC.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-06-2005/0004162849&EDATE=)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May